- $6.07m
- -$0.38m
- $0.12m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.47 | ||
| Price to Tang. Book | 1.47 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 50.86 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -229.23% | ||
| Return on Equity | -248.98% | ||
| Operating Margin | -7907.77% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2.36 | 0.82 | 0.95 | 0.84 | 0.12 | n/a | 1 | -51.89% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
Directors
- Christopher Schaber CHM (54)
- Jonathan Guarino CFO (49)
- Oreola Donini SVP (49)
- Richard Straube SVP (69)
- Gregg Lapointe IND (62)
- Diane Parks IND (68)
- Robert Rubin IND (75)
- Jerome Zeldis IND (72)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 16th, 1987
- Public Since
- April 4th, 1994
- No. of Shareholders
- 186
- No. of Employees
- 14
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 3,155,603
- Address
- 29 Emmons Drive, Suite B-10, PRINCETON, 08540
- Web
- https://www.soligenix.com/
- Phone
- +1 6095388200
- Auditors
- Cherry Bekaert LLP
Upcoming Events for SNGX
Soligenix Inc Annual Shareholders Meeting
Q2 2025 Soligenix Inc Earnings Release
Similar to SNGX
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Soligenix share price?
As of Today at 23:21 UTC, shares in Soligenix are trading at $1.92. This share price information is delayed by 15 minutes.
How has the Soligenix share price performed this year?
Shares in Soligenix last closed at $1.92 and the price had moved by -70.27% over the past 365 days. In terms of relative price strength the Soligenix share price has underperformed the S&P500 Index by -73.19% over the past year.
What are the analyst and broker recommendations for Soligenix?
The overall consensus recommendation for Soligenix is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Soligenix dividend yield?
Soligenix does not currently pay a dividend.
Does Soligenix pay a dividend?
Soligenix does not currently pay a dividend.
When does Soligenix next pay dividends?
Soligenix does not currently pay a dividend.
How do I buy Soligenix shares?
To buy shares in Soligenix you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Soligenix?
As of the previous close price of $1.92, shares in Soligenix had a market capitalisation of $6.07m.
Where are Soligenix shares listed?
Here are the trading details for Soligenix:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: SNGX
What kind of share is Soligenix?
Based on an overall assessment of its quality, value and momentum Soligenix is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Soligenix share price forecast for 2025?
The analyst consensus target price for shares in Soligenix is $22.50. That is 1069.44% above the last closing price of $1.92.
Analysts covering Soligenix currently have a consensus Earnings Per Share (EPS) forecast of -$3.09 for the next financial year.
Find out moreWhat is the trend in the Soligenix share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Soligenix. Over the past six months, its share price has underperformed the S&P500 Index by -49.93%.
As of the last closing price of $1.92, shares in Soligenix were trading -39.05% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Soligenix PE Ratio?
The Soligenix PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.92.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Soligenix?
Soligenix's management team is headed by:
- Christopher Schaber - CHM
- Jonathan Guarino - CFO
- Oreola Donini - SVP
- Richard Straube - SVP
- Gregg Lapointe - IND
- Diane Parks - IND
- Robert Rubin - IND
- Jerome Zeldis - IND